TollB-001 / Toll Biotech - LARVOL DELTA

Tolling Biotech's Category 1 rare disease new drug obtains FDA clinical approval for systemic sclerosis [Google translation] (Sina Corp) - "On February 5, Toll Biotech announced that its rare disease category 1 new drug TollB-001 tablets, following the clinical approval by China's NMPA on December 30, 2024, has been approved by the US FDA for the treatment of systemic sclerosis. This progress marks another important step for Toll Biotech in the field of global autoimmune diseases."

China approval • FDA approval • Systemic Sclerosis

A Study of Single and Multiple Oral Doses of TollB-001 (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Toll Biotech Co. Ltd. (Beijing)

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology